Royalty Pharma, a leading biopharmaceutical royalty company, is set to release its quarterly earnings on Wednesday, November 6th. Analysts anticipate an EPS of $0.93, and investors are keen to see if the company surpasses expectations and provides positive guidance. This article delves into Royalty Pharma’s past performance, analyst insights, and peer comparisons, providing a comprehensive overview of key factors influencing the upcoming earnings release.